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A B S T R A C T
Here we describe the generation of induced pluripotent stem cell (iPSC) lines from peripheral blood samples of identical twin sisters with type 2 diabetes mellitus
(DM2). Two clonal lines from each patient (HU-DM2-A-1, HU-DM2-A-2 and HU-DM2-B-1, HU-DM2-B-2) were established via Sendai viral reprograming of peripheral
blood mononuclear cells, and characterized to confirm pluripotency and genetic integrity. The established iPSC lines can help to investigate DM2 related cellular
phenotypes and provide a model system for drug testing.
1. Resource Table












Institution 1. Research Center for Natural Sciences, Institute of











Multiline rationale isogenic clones of DM2 patients and control and patient
(atherosclerosis) pairs
Gene modification NO
Type of modification NA
Associated disease Diabetes; atherosclerosis
Gene/locus NA
Method of modification NA












Ethical approval Health Care Research Council, Human Reproduction
Committee in Hungary (in Hungarian: Egészségügyi
Tudományos Tanács, Humán Reprodukciós Bizottság (ETT
HRB)Approval number: 42592-2/2016-EHR
2. Resource utility
DM2 is regarded as metabolic disease resulting from insulin re-
sistance of peripheral tissues and inadequate insulin-secreting pan-
creatic cell function. It is one of the largest global health burdens
having frequent complications related to chronic hyperglycemia
(Harding et al, 2019.). Generation of disease specific iPSC lines offers a
platform to improve therapeutic options.
3. Resource details
Even though diabetes is one of the most studied diseases all over the
world, treatment opportunities for diabetic patients remain limited.
iPSC technology provides a new opportunity for investigation and
treatment of the disease. Along with the investigation of iPSC-derived
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insulin producing beta cells (Gaertner et al., 2019.) there is an in-
creasing number of studies focusing other affected-derived cell types
such as cardiac or mesenchymal cells derived from diabetic patients’
samples (Granéli et al., 2019., Balhara et al., 2015.). Generation of well
characterized iPSC lines from patients diagnosed with diabetes could
help to understand the involvement of different cell types in the pa-
thology of diabetes. Here we describe four iPSC clones generated from
identical twin patients diagnosed with idiopathic DM2, in whom the
gene loci for diabetes are unknown (Tables 1 and 2).
Peripheral blood samples of the 66-year-old twin sisters were taken
at the Heart and Vascular Center, Semmelweis University. One of the
two patients had developed atherosclerosis as well, possibly due to her
smoking habits. Mononuclear cell fractions of the samples were re-
programed via Sendai viral transduction of the four “classical”
Yamanaka factors (Oct3/4, Sox2, klf4, cMyc). Two clones of each pa-
tient specific iPSC-s were selected and characterized. All four clones
displayed normal diploid 46, XX karyotype (Fig. 1.A) according to
standard G-banding and their identity was verified by STR analysis.
After passage 12 real time quantitative PCR analysis (RT-PCR) using
Sendai virus specific primers revealed clearance of viral particles
(Fig. 1.B). According to our lab routine we used the 62F iPCS line
generated from fibroblast sample of a healthy volunteer by Sendai virus
(Vőfély et al. 2018.) as negative control for SeV assessment. Myco-
plasma tests were negative (see Supplementary file).
Pluripotency was confirmed by assessment of morphology
(Fig. 1.C), immunofluorescent staining of endogenous pluripotency
transcription factors Oct4 and Nanog (Fig. 1.D), as well as flow cyto-
metry analysis of surface marker SSEA4 (Fig. 1.E). In vitro spontaneous
differentiation potential was examined via embryoid body (EB) for-
mation. Derivatives of the three germ layers were evinced by im-
munofluorescent staining after 6 days of differentiation in free-floating
EB culture and additional 12 days on gelatine coated chambered cover
glasses. Expression of alpha-fetoprotein (AFP) as endoderm, smooth
muscle actin (SMA) as mesoderm and beta-III tubulin (TUB) as ecto-
derm markers were detected by confocal microscopy (Fig. 1.F). Besides
RNA expression levels of pluripotency marker Nanog, endoderm marker
AFP, mesoderm marker brachyury (BRY) and ectoderm marker Paired
Box 6 (PAX6) were compared in iPS and 6 + 6 days differentiated EB
cultures by RT-PCR. In pooled RNA samples of 8 parallel differentia-
tions we found considerable downregulation of pluripotency-, and up-
regulation of differentiation markers similar to HUES9 human em-
bryonic cell line that we used as a positive control (Erdei et al., 2014.)
(Fig. 1.G).
The characterization and quality control of the established cell lines
verified the pluripotency and the genomic integrity of the iPSC clones.
4. Materials and methods
4.1. Reprogramming of peripheral blood mononuclear cells (PBMC)
PBMCs were prepared according to manufacturer’s instruction (BD
Vacutainer CPT). iPSC lines were generated from PBMC by Sendai virus
(Thermo Fisher Scientific) based reprogramming and manually selected
clones were maintained on mitomycin-C (Sigma) treated mouse em-
bryonic fibroblast feeder cells (Millipore) until passage 10. Clones were
transferred onto Matrigel (Corning) coated plates in mTeSR medium
(Stemcell Technologies) and medium was changed every day. Cells
were passaged with Accutase (Thermofisher Scientific) when reached




iPSC line names Abbreviation in figures Gender Age Ethnicity Genotype of locus Disease
RCNSi001-A HU-DM2-A-1 Female 66 Caucasian NA DM2
RCNSi001-B HU-DM2-A-2 Female 66 Caucasian NA DM2
RCNSi002-A HU-DM2-B-1 Female 66 Caucasian NA DM2, atherosclerosis
RCNSi002-B HU-DM2-B-2 Female 66 Caucasian NA DM2, atherosclerosis
Table 2
Characterization and validation.
Classification Test Result Data
Morphology Photography
Olympus CKX 41
Normal iPSCs formation Fig. 1 panel C
Phenotype Qualitative analysis
Immunocytochemistry
Positive staining of pluripotency markers: Oct4, Nanog Fig. 1 panel D
Quantitative analysis Flow cytometry
RT-qPCR
Cell surface markers:
SSEA-4: > 90% all of cell lines
RT-qPCR: Nanog, Brachyury, AFP, PAX6
Fig. 1 panel E, G
Genotype Karyotype (G-banding) and resolution 46XX for all clones
Resolution: 450–500 bands per haploid chromosome set
Fig. 1 panel A
Identity STR analysis DNA Profiling performed Supplementary file STR
analysis.





Southern Blot OR WGS NA
Microbiology and virology Mycoplasma Mycoplasma testing /Negative Supplementary file
mycoplasma test.
Differentiation potential Embryoid body formation (Spontaneous
differentiation)
Immunocytochemistry of AFP, SMA and B-III-TUBULIN as germ layer
markers. mRNA expression of AFP, BRY and PAX6 as germ layer
markers.
Fig. 1 panel F, G




Blood group genotyping NA
HLA tissue typing NA
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4.2. Karyotype and STR analyses
Analyses were performed by UD-GENOMED Medical Genomic
Technologies Ltd. (Hungary). Chromosomes were classified using the
standard G-banding technique between passages p14-25. STR analysis
was performed by GenePrint® 10 System (Promega).
4.3. Mycoplasma detection
Mycoplasma detection was performed with MyxoAlertTM
Mycoplasma Detection Kit (Lonza) according to the manufacturer’s
instructions.
4.4. In vitro spontaneous differentiation
For in vitro spontaneous differentiation experiments, iPSCs were
detached with collagenase (Thermofisher Scientific) and transferred to
ultra-low attachment plates (Nalgene Nunc International) to allow
embryoid body (EB) formation. EB medium (KO-DMEM supplemented
with 20% FBS, 1 mM L-GLU, 1% non-essential amino acids, and 0,1 mM
ß-mercaptoethnol (Thermofisher Scientific)) was changed in every
2 days for 6 days. Then EBs were transmitted onto 0.1% gelatine
(Merck) coated eight-well Nunc Lab-Tek II Chambered Coverglasses
(Nalgene Nunc International) for subsequent immunocytochemical
staining, or 24 well tissue culture plates (Avantor) for subsequent RT-
PCR analysis, and allowed to attach and differentiate spontaneously for
another 12 or 6 days in DMEM supplemented with 10% FBS.
4.5. RT-PCR analysis
Total RNA was isolated from iPSCs using TriFast reagent (Peqlab
Ltd.) following the manufacturer's instructions. cDNA samples were
prepared from 1 μg total RNA using the Promega Reverse Transcription
System Kit (Promega) as specified by the manufacturer. For real-time
quantitative PCR (RT-PCR) Pre- Developed TaqMan® assays were pur-
chased (Thermo Fisher Scientific). RPLP0 ribosomal protein was used as
endogenous control. RT-PCR analyses were carried out in StepOnePlus™
Real-Time PCR System (Thermo Fisher Scientific). Relative mRNA le-
vels were calculated by the 2−ΔCt method.
4.6. Immunocytochemical staining
For immunofluorescence staining, iPSCs clones and their sponta-
neously differentiated derivates cells were plated on eight-well cham-
bers as described previously (Erdei et al., 2014.). Briefly; cells were
fixed on the indicated days with 4% paraformaldehyde (Thermo Fisher
Scientific) in Dulbecco's modified PBS (DPBS) (Sigma) for 15 min at
room temperature. After washing with DPBS, the samples were blocked
for 1 h at room temperature in DPBS containing 2 mg/ml bovine serum
albumin (BSA-Sigma), 1% gelatine from cold water fish skin (Sigma),
0.1% Triton-× 100 (Sigma) with or without 5% goat serum (Sigma)
depending on the primary antibodies. The samples were then incubated
for 1 h at room temperature or overnight at 4 °C with the primary
antibodies (Table 3.). After washing with DPBS, the cells were in-
cubated for 1 h at room temperature with Alexa Fluor 488-conjugated
IgG secondary antibodies (Thermo Fisher Scientific). The nuclei were
stained with DAPI (Thermo Fisher Scientific).
Fig. 1. Characterization of induced pluripotent stem cell lines (HU-DM2-A-1, HU-DM2-A-2, HU-DM2-B-1 and HU-DM2-B-2). A. Karyotype analysis of iPSC clones B.
Sendai virus clearance by RT-PCR C. Immunofluorescence staining of pluripotency markers (NANOG and OCT4). D. Cell surface expression of SSEA4 by flow
cytometry E. Immunofluorescence staining of germ layer markers (AFP as endoderm, SMA as mesoderm and beta-III tubulin (TUB) as ectoderm markers). F.
Expression of pluripotency and differentiation markers by RT-PCR.
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Table 3
Reagents details.
Antibodies used for immunocytochemistry/flow-citometry
Antibody Dilution Company Cat # and RRID
Pluripotency marker Mouse anti-Oct3/4 1:50 Santa Cruz Biotechnology Cat# sc-5279;
RRID:AB_628051
Pluripotency marker Goat anti-Nanog 1:100 R and D Systems Cat# AF1997; RRID:AB_355097
Endoderm marker Mouse anti-AFP 1:500 Sigma-Aldrich Cat# A8452; RRID:AB_258392
Mesoderm marker Mouse anti-SMA 1:500 Abcam Cat# ab7817; RRID:AB_262054
Ectoderm marker Mouse anti-ß-III-Tubulin 1:2000 R and D Systems Cat# MAB1195; RRID:AB_357520
Secondary antibody Goat-Anti-Mouse (H + L) Cross-Adsorbed Secondary Antibody,
Alexa Fluor 488
1:250 Thermo Fisher Scientific Cat# A-11029;
RRID:AB_2534088
Secondary antibody Donkey-Anti-Goat (H + L) Cross-Adsorbed Secondary Antibody,
Alexa Fluor 488
1:250 Thermo Fisher Scientific Cat# A-11055;
RRID:AB_2534102
Primers
Sendai viral vector Sendai-SevFam Mr04269880_mr (Applied Biosystems)
Pluripotency Markers (qPCR) NANOG Hs02387400_g1 (Thermo Fisher Scientific)
Pluripotency Markers (qPCR) OCT4 Hs00999632_g1 (Thermo Fisher Scientific)
Endoderm differentiation marker (qPCR) AFP Hs00173490_m1 (Thermo Fisher Scientific)
Mesoderm differentiation markers (qPCR) T-BRY Hs00610080_m1 (Thermo Fisher Scientific)
Ectoderm differentiation markers (qPCR) PAX6 Hs00240871_m1 (Thermo Fisher Scientific)
House-Keeping Gene (qPCR) RLP0 Hs99999902_m1 (Thermo Fisher Scientific)
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